SPC313
Saxagliptín/dapaglíflózín
Status:
UmsóknApplication date:
2.9.2020Application published:
15.9.2020
Max expiry date:
18.7.2031Medicine name:
QternMedicine for children:
No
Timeline
Today
2.9.2020Application
15.9.2020Publication
18.7.2031Expires
Marketing license
IS authorization number:
EU/1/16/1108/001-004Date:
25.7.2016
Foreign authorization number:
EU/1/16/1108Date:
15.7.2016
Owner
Name:
AstraZeneca ABAddress:
, 151 85 Södertälje SE
Agent
Name:
Kjartan Ragnars, hrl.Address:
Hrauntungu 66, 200 Kópavogi
Patent
Number:
EP2139494